Skip to main content
Terug
Watch Compare

HERON THERAPEUTICS, INC. /DE/

Datakwaliteit: 83%
HRTX
Nasdaq Manufacturing Chemicals
€ 0,82
▼ € 0,01 (-1,44%)
Marktkapitalisatie: 154,66 M
Prijs
€ 0,82
Marktkapitalisatie
154,66 M
Dagbereik
€ 0,80 — € 0,83
52-Weeksbereik
€ 0,74 — € 2,61
Volume
1.019.274
Openen € 0,83
50D / 200D Gem.
€ 1,07
23,66% below
50D / 200D Gem.
€ 1,35
39,35% below

Quick Summary

Belangrijkste Punten

Negative free cash flow of -27,91 M

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
N/A
ROIC-3,02%
Net MarginN/A
Op. MarginN/A

Veiligheid

Debt / Equity
N/A
Current Ratio2,56
Interest Coverage-0,26

Waardering

PE (TTM)
-7,66
Onder sectorgemiddelde (-1,48)
P/B Ratio10,39
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1364 peers)
Metriek Aandeel Sector Mediaan
P/E -7,7 -1,5
P/B 10,4 1,6
ROE % — -53,4
Net Margin % — -41,5
Rev Growth 5Y % — 1,8
D/E — 0,3

ETFs Holding This Stock

IWV logo IWV iShares Russell 3000 ETF
0,00% weight

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -20,20 M
ROE N/A ROA -8,40%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -27,91 M
ROIC -3,02% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 2,56
Interest Coverage -0,26 Asset Turnover N/A
Working Capital 139,69 M Tangible Book Value 14,89 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -7,66 Forward P/E N/A
P/B Ratio 10,39 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -18,05%
Market Cap 154,66 M Enterprise Value 111,59 M
Per Share
EPS (Diluted TTM) -0,12 Revenue / Share N/A
FCF / Share -0,15 OCF / Share -0,15
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 138,19%
SBC-Adj. FCF -38,79 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue — — — — —
Net Income -20,20 M -13,58 M -110,56 M -182,02 M -220,68 M
EPS (Diluted) -0,12 -0,09 -0,80 -1,67 —
Gross Profit 113,56 M 105,64 M 61,94 M — —
Operating Income -2,54 M -11,53 M -110,62 M -174,66 M -217,83 M
EBITDA — — — — —
R&D Expenses 12,43 M 16,68 M 55,90 M 107,51 M 130,82 M
SG&A Expenses — — — — —
D&A 2,31 M 2,49 M 2,90 M 2,89 M 3,02 M
Interest Expense 9,61 M 6,03 M 3,87 M 2,47 M 2,41 M
Income Tax 0,0 0,0 0,0 0,0 0,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 255,88 M 233,15 M 222,51 M 250,95 M 305,71 M
Total Liabilities 241,54 M 266,80 M 256,48 M 237,38 M 228,14 M
Shareholders' Equity 14,33 M -33,65 M -33,97 M 13,57 M 77,57 M
Total Debt — — — — —
Cash & Equivalents 28,65 M 25,80 M 28,68 M 15,36 M 90,54 M
Current Assets 238,07 M 209,01 M 188,77 M 205,44 M 254,42 M
Current Liabilities 96,10 M 91,46 M 79,69 M 82,36 M 71,06 M